Online Informative Session – C-Path’s Translational Therapeutics Accelerator (TRxA)

Date: 23 January 2025

Time: 16h00 – 17h00

Via Zoom (link here)

In this webinar presented by Maaike Everts (Executive Director of the TrxA), we will cover:

• • An overview of the new RFP, encompassing both large and small molecules;
  • Detailed information about the types of projects eligible for funding, including those for novel protein-based therapeutics, gene-based therapies and small molecules;
  • Eligibility criteria and application procedures for this funding opportunity;
  • Insights into how TRxA supports projects through the drug development valley of death to enhance licensing prospects.

Learn more about our speaker:

Maaike Everts, PhD, a pharmaceutical scientist with broad experience in drug delivery, discovery and development, is Executive Director of the Critical Path Institute’s Translational Therapeutics Accelerator. Prior to C-Path, she had a leadership role with Parenteral Drug Delivery Solutions at Evonik Health Care, responsible for shaping the drug delivery technology and manufacturing platforms offered by the organization as well as positioning them in the marketplace. Before joining Evonik, Maaike was a full professor at the University of Alabama at Birmingham (UAB), in the School of Medicine, where she structured and lead the Alabama Drug Discovery Alliance, a venture between UAB and Southern Research, and the Antiviral Drug Discovery and Development Consortium, funded by the National Institutes of Health. She had been at UAB since 2002, initially as a postdoctoral scholar in its Gene Therapy Center, where she combined adenoviral based vectors with nanotechnology. She received her Ph.D. in Pharmacokinetics and Drug Delivery from the University of Groningen in the Netherlands.

We look forward to welcoming you to this Online Session.